Q3 2025 LifeMD Inc Earnings Call Transcript
Key Points
- LifeMD Inc (LFMD) reported a strong year-over-year performance with Telehealth revenue up 18% and adjusted EBITDA increasing 30% compared to the prior year period.
- The company added approximately 10,000 net new subscribers to its RexMD business, indicating a return to growth.
- LifeMD Inc (LFMD) secured regulatory approval for its nonsterile 503-A compounding pharmacy, which will enhance its ability to produce personalized medications at scale.
- The company successfully divested its majority interest in WorkSimpli, strengthening its balance sheet and allowing it to focus on its core virtual care and pharmacy business.
- LifeMD Inc (LFMD) is well-positioned for significant growth in 2026, with strategic collaborations with Novo Nordisk and Eli Lilly expected to drive growth in its weight management offering.
- LifeMD Inc (LFMD) faced challenges in the weight management category due to intense competition from low-cost compounded GLP-1 marketers.
- The company's gross margin for the third quarter was 88%, a decline of 290 basis points versus the prior year due to revenue mix.
- LifeMD Inc (LFMD) reported a GAAP net loss attributable to common stockholders for the third quarter of 2025 of $4.6 million.
- The transition from compounded to branded therapies in weight management has impacted the company's gross margins.
- Insurance enablement has been slower to deploy on LifeMD Inc (LFMD)'s platform than planned, impacting potential revenue growth.
Good afternoon. Thank you for joining us today to discuss LifeMD's results for the third quarter ended September 30, 2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session.
Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings, and within other filings that LifeMD may make with the SEC from time to time.
Forward-looking statements made during this call are based on current information available to the company as of today, November 1, 2025. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Also, please note that management will be discussing certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
